In the Yaz, Yasmin, and Ocella multicounty litigation (MCL) in the Superior Court of New Jersey in Bergen County, the court filed a new case management order in mid-October. The court document concerns an extension of the discovery deadline, in addition to the next case management conference, which will be on November 21, 2013. The Yaz MCL is being heard by Judge Brian R. Martinotti.
MCLs like multidistrict litigations (MDLs) are created for efficiency. However, delaying the discovery process in order to build a stronger case, via the gathering of more evidence, means that both parties will be better prepared when it comes time for the bellwether trial process. This is a smart move on the part of the court, as having a dearth of evidence in the first bellwether trials could delay the legal process further.
Even so, the case management order does not reveal the reason for extending the deadline beyond the original date of December 31, 2013 to June 30, 2014.
As of late October, there are 390 cases pending in the Yaz MCL in New Jersey.
Yaz attorneys at Carey Danis & Lowe continue to hear from women who have experienced adverse side effects after using Yaz. In April 2012, the U.S. Food and Drug Administration (FDA) released a safety announcement in which they detail their review of recent Yaz studies looking at the link between the risk of Yaz blood clots while using an oral contraceptive like Yaz, Yasmin, or Ocella. After reviewing the data, the FDA concluded that there may be a strong link between Yaz and blood clots.
Assistance for Yaz Victims
If you are concerned about Yaz side effects, speak with one of Carey Danis & Lowe’s on-staff nurses.
Carey Danis & Lowe is currently accepting Yaz cases, so if you believe that your injuries were caused by Yaz, Yasmin, or Ocella, get in touch with one of our Yaz attorneys to discuss your compensation eligibility and to file a Yaz blood clot lawsuit.
Contact Carey Danis & Lowe today by calling 800.721.2519, or by completing a confidential personal injury claim.References: Pharmaceutical litigation, Yaz/Yasmin